SDI-118
Phase 1- Indications
- Cognitive impairment, Alzheimer's disease, Major depressive disorder
Company intelligence / Profile preview
Syndesi Therapeutics
Ottignies-Louvain-la-Neuve, Wallonie, Belgiumnews.abbvie.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Lead molecule SDI-118 was in Phase 1b studies at the time of acquisition, being evaluated to target nerve terminals to enhance synaptic efficiency
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
UCB Biopharma SRL
Beyond the preview
Go deeper on Syndesi Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syndesi Therapeutics.